Government-Owned Inventions; Availability for Licensing, 51968 [2018-22317]

Download as PDF 51968 Federal Register / Vol. 83, No. 199 / Monday, October 15, 2018 / Notices commercialization of results of federally-funded research and development. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health FOR FURTHER INFORMATION CONTACT: National Human Genome Research Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Human Genome Research Institute Special Emphasis Panel. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Human Genome Research Institute Special Emphasis Panel; Charles Lee Application 2 U24 HG007479–05. Date: November 9, 2018. Time: 5:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Residence Inn Bethesda Downtown, 7355 Wisconsin Avenue, Room Calvert II, Bethesda, MD 20814 (Telephone Conference Call). Contact Person: Keith McKenney, Ph.D., Scientific Review Officer, NHGRI, 5635 Fishers Lane, Suite 4076, Bethesda, MD 20814, 301–594–4280, mckenneyk@ mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: October 5, 2018. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–22314 Filed 10–12–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health khammond on DSK30JT082PROD with NOTICES Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious SUMMARY: VerDate Sep<11>2014 21:34 Oct 12, 2018 Jkt 247001 Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUPPLEMENTARY INFORMATION: Technology description follows. TSLP for treatment of pulmonary methicillin-resistant S. aureus (MRSA) infection. Available for licensing and commercial development is a patent estate covering methods of promoting the host defense of a patient suffering from or at risk of a bacterial infection (Methicillin-resistant Staphylococcus aureus (MRSA) infection in particular) by administering a thymic stromal lymphopoeitin (TSLP) protein or polypeptide. TSLP induces neutrophil mediated killing of MRSA bacteria mediated by reactive oxygen species and complement. Community-acquired Staphylococcus aureus infections often present as serious skin infections in otherwise healthy individuals and have become a worldwide epidemic fueled by the emergence of strains with antibiotic resistance. The cytokine TSLP is highly expressed in the skin and in other barrier surfaces and plays a deleterious role by promoting T helper cell type 2 (TH2) responses during allergic diseases. The present methodology is based on a finding of non-TH2’s role for TSLP in enhancing neutrophil killing of MRSA during an in vivo skin infection. TSLP also enhances killing of Streptococcus pyogenes, another clinically important cause of human skin infections. Unexpectedly, TSLP mechanistically mediates antibacterial effects by directly engaging the complement C5 system to modulate production of reactive oxygen species by neutrophils. Potential Commercial Applications: • MRSA infection. Inventors: Warren Leonard, Erin West, Rosanne Spolski (all of NHLBI) and Christopher Garcia (Stanford). Relevant Publications: • J Immunol May 1, 2016, 196 (1 Supplement) 60.5; • Sci Immunol. 2016 Nov 18;1(5). Intellectual Property: HHS Reference No. E–034–2016, Licensing Contact: Michael Shmilovich, Esq, CLP; 301–435–5019; shmilovm@mail.nih.gov. PO 00000 Frm 00046 Fmt 4703 Sfmt 9990 Dated: September 25, 2018. Michael A. Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2018–22317 Filed 10–12–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel Global Infectious Disease Research Administration Development Award for Low- and Middle-Income Country Institutions (G11). Date: November 6, 2018. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Zhuqing (Charlie) Li, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room # 3G41B, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892–9834, (240) 669– 5068, zhuqing.li@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: October 5, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–22313 Filed 10–12–18; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\15OCN1.SGM 15OCN1

Agencies

[Federal Register Volume 83, Number 199 (Monday, October 15, 2018)]
[Notices]
[Page 51968]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-22317]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: Technology description follows.
    TSLP for treatment of pulmonary methicillin-resistant S. aureus 
(MRSA) infection. Available for licensing and commercial development is 
a patent estate covering methods of promoting the host defense of a 
patient suffering from or at risk of a bacterial infection 
(Methicillin-resistant Staphylococcus aureus (MRSA) infection in 
particular) by administering a thymic stromal lymphopoeitin (TSLP) 
protein or polypeptide. TSLP induces neutrophil mediated killing of 
MRSA bacteria mediated by reactive oxygen species and complement. 
Community-acquired Staphylococcus aureus infections often present as 
serious skin infections in otherwise healthy individuals and have 
become a worldwide epidemic fueled by the emergence of strains with 
antibiotic resistance. The cytokine TSLP is highly expressed in the 
skin and in other barrier surfaces and plays a deleterious role by 
promoting T helper cell type 2 (TH2) responses during allergic 
diseases. The present methodology is based on a finding of non-TH2's 
role for TSLP in enhancing neutrophil killing of MRSA during an in vivo 
skin infection. TSLP also enhances killing of Streptococcus pyogenes, 
another clinically important cause of human skin infections. 
Unexpectedly, TSLP mechanistically mediates antibacterial effects by 
directly engaging the complement C5 system to modulate production of 
reactive oxygen species by neutrophils.
    Potential Commercial Applications:
     MRSA infection.
    Inventors: Warren Leonard, Erin West, Rosanne Spolski (all of 
NHLBI) and Christopher Garcia (Stanford).
    Relevant Publications:
     J Immunol May 1, 2016, 196 (1 Supplement) 60.5;
     Sci Immunol. 2016 Nov 18;1(5).
    Intellectual Property: HHS Reference No. E-034-2016,
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: September 25, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-22317 Filed 10-12-18; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.